Evaluation of the expression level of miR-140-5p in MS patients’ comparison with healthy controls and their association with clinical factors

• Main Authors: Fariba banitalebi, Somayeh Reiisi
• Format: Article
• Language: fas
• Published: Shahid Sadoughi University of Medical Sciences 2018-12-01
• Series: Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd
• Subjects: Multiple sclerosis; miR-140-5p; qPCR; biomarker.
• Online Access: http://jssu.ssu.ac.ir/browse.php?a_code=A-10-3218-2&slc_lang=en&sid=1

Introdution: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Nevertheless, the causal etiology of MS is not fully revealed and there are some neurological disorders that might have similar phenotypic manifestations with MS. Therefore, reliable and available diagnostic method is very necessary for differential diagnosis. The use of new biomarkers for faster diagnosis and selection of more efficient therapies is one of the main concerns in this area. Few studies have been conducted on the effects of miR-140-5p in T cell development. Therefore, to determine the role of this miRNA in MS, this study was directed to investigate the expression level in MS samples and its relationship with clinical factors. Methods: In this study, expression level of miR-140-5p was evaluated in 40 MS patient and 40 health individual by using qPCR. Followed total RNA extraction, expression was investigated by miRNA specific primers by stem-loop method and then statistical analysis was accomplished to define the significance. In the next step, the correlation between clinical factors and miRNA expression was considered. Results: The results of the present study showed that relative expression of miR-140-5pwas significantly decreased in MS patient compared with the control group (P<0.001). Conclusion: As a result, miR-140-5p may contribute to MS disease, so that decrease in its expression is associated with increased disability. Further investigation can help to suggest this miRNA as diagnostic biomarkers or therapeutic targets in MS.